GlassScriptPhysician profile
Barry S Citron
NPI 1942232301
$1,931.59
in general payments reported to CMS, 2019-2025
26 companies · $238 in 2025
The $238 reported for 2025 was less than what a typical Plastic Surgery provider received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $281 · 2020: $148 · 2021: $186 · 2022: $418 · 2023: $295 · 2024: $366 · 2025: $238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $899.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $898.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $460.23 | 2019-2022 | |
| Incyte Corporation | $228.26 | 2022-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $202.11 | 2020-2025 | Blu-U, Odomzo |
| Leo Pharma INC. | $178.86 | 2019-2023 | Adbry |
| Dermavant Sciences, INC. | $124.98 | 2024 | Vtama |
| Kerecis Limited | $114.46 | 2024-2025 | Kerecis Surgiclose, Kerecis Omega3 Marigen, Kerecis Graftguide |
| Abbvie INC. | $85.73 | 2023-2025 | |
| Janssen Biotech, INC. | $50.20 | 2023-2024 | Simponi Aria, Stelara, Simponi |
| Mayne Pharma Commercial LLC | $45.24 | 2019-2020 | |
| Mentor Worldwide LLC | $44.12 | 2022 | |
| Blueprint Medicines Corporation | $42.45 | 2023-2024 | Ayvakit |
| Convatec INC. | $41.93 | 2025 | |
| Lilly USA, LLC | $38.10 | 2023-2024 | Ebglyss, Taltz |
| E.R. Squibb & Sons, L.L.C. | $31.89 | 2022-2024 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $30.59 | 2021-2023 | Duobrii, Arazlo, Jublia |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $30.37 | 2022-2024 | Otezla |
| Biofrontera INC. | $30.00 | 2019 | |
| Sandoz INC. | $23.14 | 2021 | |
| Mission Pharmacal Company | $18.96 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $18.56 | 2025 | Libtayo |
| Revance Therapeutics, INC. | $16.36 | 2025 | Daxxify |
| Almirall LLC | $15.86 | 2022 | |
| Galderma Laboratories, L.P. | $15.49 | 2025 | |
| Journey Medical Corporation | $15.31 | 2023 | |
| Sebela Pharmaceuticals INC. | $14.99 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.40 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Citron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.